Trials / Completed
CompletedNCT00498745
Study Comparing 2 New Formulations of HKI-272 in Healthy Adult Subjects
A Single Dose Bioavailability Study of 2 New Formulations of HKI-272 (240 mg) Compared With a Reference Capsule and an Oral Solution in Healthy Adult Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 36 (planned)
- Sponsor
- Puma Biotechnology, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Accepted
Summary
To evaluate the comparative bioavailability of 2 new tablet formulations of HKI-272 with a reference capsule and an oral solution in healthy subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | neratinib | HKI-272 |
Timeline
- Start date
- 2007-07-01
- Completion
- 2007-09-01
- First posted
- 2007-07-10
- Last updated
- 2012-05-14
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00498745. Inclusion in this directory is not an endorsement.